↓ Cooling
Business
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
AstraZeneca reports significant Phase III trial wins for Tozorakimab, a COPD drug showing broad benefits for current and former smokers.